News & Events

News

Our latest Press Releases

Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024

August 5, 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

June 27, 2024

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

June 20, 2024

EVENTS

Meet Tubulis live

Ovarian Cancer Research Symposium, Seattle

September 20-21, 2024

Festival of Biologics, Basel

October 15-17, 2024

ENA 2024, Barcelona

October 23-35, 2024

TPD & Induced Proximity Summit, Boston

October 28–31, 2024

Jefferies London Healthcare Conference

November 19-21, 2024